Phaseline

Companies › Theravia

Theravia: clinical trials, targets and expected readouts

1 active drug program in 14 registered trials: 7 Phase 2, 4 Phase 1, 2 Phase 4, 1 Phase 3; Hematology, Immunology, Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Hydroxyurea
Ribonucleoside-diphosphate reductase RR1 inhibitor
RRM1, RRM2B, RRM2Phase 2Sickle Cell Disease; Sickle Cell Anemia (HbSS); Sickle Cell Anemia in Children; Primary Immunodeficiency (PID) …Feb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01962415HydroxyureaPhase 2Primary Immunodeficiency (PID)ImmunologyNov 2026
NCT07177300HydroxyureaPhase 4Sickle Cell Anemia (HbSS)HematologyDec 2026
NCT00920972HydroxyureaPhase 1Metabolic DisordersOncologyDec 2026
NCT03948867HydroxyureaPhase 2Sickle Cell Anemia in ChildrenHematologyDec 2026
NCT05285917HydroxyureaPhase 3Sickle Cell Anemia in ChildrenHematologySep 2027
NCT06171217HydroxyureaPhase 2Sickle Cell DiseaseHematologyOct 2027
NCT06578507HydroxyureaPhase 2Sickle Cell DiseaseHematologyFeb 2028
NCT06761560HydroxyureaPhase 2Sickle Cell Disease (SCD)HematologyNov 2028
NCT04362293HydroxyureaPhase 2Sickle Cell DiseaseHematologyAug 2029
NCT04362293HydroxyureaPhase 2Sickle Cell DiseaseHematologyAug 2029
NCT06199557HydroxyureaPhase 1Acute Myeloid Leukemia, AdultOncologySep 2029
NCT06526117HydroxyureaPhase 4Sickle Cell DiseaseHematologyDec 2029
NCT07708714HydroxyureaPhase 1Sickle Cell DiseaseHematologyNov 2030
NCT01966731HydroxyureaPhase 1Sickle Cell DiseaseHematologyAug 2033

Targets

RRM1 (1) RRM2B (1) RRM2 (1)

Companies with the same targets

Beijing Immunochina Medical Science & Technology Jiangsu Healthy Life Innovation Medical Technology InnoPharmax Jiangsu Hansoh Pharmaceutical

Companies built like this

InnoPharmax Electra Therapeutics Syntrix Biosystems Tavotek Biotherapeutics Xizang Haisco Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.